Table S3 from Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
David J. Kwiatkowski(Brigham and Women's Hospital), Sabina Signoretti(Brigham and Women's Hospital), Kathryn P. Gray(Dana-Farber Cancer Institute), Camillo Porta(University of Pavia), Jean‐Christophe Pignon(Brigham and Women's Hospital), Brian I. Rini(Vanderbilt University Medical Center), Pablo M. Barrios, M. Dror Michaelson(Harvard University), Eliezer M. Van Allen(Dana-Farber Cancer Institute), Lana Hamieh(Brigham and Women's Hospital), Aaron R. Thorner(Center for Cancer Research), Toni K. Choueiri(Harvard University), Thai H. Ho(Mayo Clinic in Arizona), Magdalena E. Tyburczy(Instytut Biologii Doświadczalnej im. Marcelego Nenckiego), Sumanta Kumar Pal(City of Hope), Laurence Albigès(Université Paris-Saclay), Joaquim Bellmunt(Dana-Farber Cancer Institute), André P. Fay(Hospital São Lucas da PUCRS), Neeraj Agarwal(University of Utah), Jiaxi Song, Guillermo de Velasco(Dana-Farber Cancer Institute), Katherine M. Krajewski(Brigham and Women's Hospital), Daniel Y.C. Heng(University of Calgary), David F. McDermott(Beth Israel Deaconess Medical Center)
Cited by 0
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k